GRAIL vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
GRAIL develops multi-cancer early detection Galleri test using cell-free DNA methylation to detect signals from 50+ cancer types in a single blood draw; spun off from Illumina in 2024; NHS-Galleri trial enrolling 140,000 participants in the UK.
About
GRAIL is a healthcare company founded in 2016 as an Illumina spinout focused on developing multi-cancer early detection tests using liquid biopsy technology. The company's flagship product Galleri is a blood test that analyzes cell-free DNA methylation patterns to detect cancer signals from over 50 cancer types, many of which lack standard screening tests, enabling detection at early stages when treatment is most effective. GRAIL raised over $3.5B from investors including Amazon and Bristol Myers Squibb and was reacquired by Illumina in 2021 before being spun off again in 2024 as an independent public company following regulatory complications. Galleri has been launched commercially and is being evaluated in large clinical studies including the NHS-Galleri trial in the UK enrolling 140,000 participants. The company represents a transformative approach to oncology that could shift cancer care from reactive treatment toward proactive screening. GRAIL's technology addresses a massive unmet need given that the majority of cancers are diagnosed at late stages when outcomes are poor.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.